NCT04300556 2026-03-13A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesEisai Inc.Phase 1/2 Recruiting182 enrolled
NCT06007586 2025-12-04Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsSichuan Cancer Hospital and Research InstitutePhase 3 Completed143 enrolled